Abstract
In men with prostate-specific antigen failure after radical radiotherapy, androgen deprivation therapy should be delayed until the site of recurrence is known to allow consideration of curative treatment options, to delay androgen deprivation therapy-related morbidity, and to enable earlier access to abiraterone and docetaxel.
Copyright © 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Publication types
-
Editorial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Androgen Antagonists* / adverse effects
-
Androgen Antagonists* / therapeutic use
-
Clinical Decision-Making / methods
-
Humans
-
Male
-
Neoplasm Metastasis* / diagnosis
-
Neoplasm Metastasis* / therapy
-
Neoplasm Recurrence, Local / diagnosis
-
Neoplasm Recurrence, Local / therapy
-
Prostate-Specific Antigen / analysis*
-
Prostatectomy / adverse effects*
-
Prostatectomy / methods
-
Prostatic Neoplasms* / pathology
-
Prostatic Neoplasms* / psychology
-
Prostatic Neoplasms* / therapy
-
Quality of Life*
-
Radiotherapy / adverse effects*
-
Radiotherapy / methods
-
Risk Assessment
-
Survival Analysis
-
Time-to-Treatment*
Substances
-
Androgen Antagonists
-
Prostate-Specific Antigen